Back to All NewsDermatology’s 2017 Game Changers
Posted By American Med Spa Association, Tuesday, January 3, 2017
Share
We asked dermatologists what they predict will be the specialty’s game-changers in 2017. This is what they had to say:
Atopic dermatitis treatment
Harper N. Price, M.D., pediatric dermatology division chief, Phoenix Children’s Hospital, tells Dermatology Times that she’s looking forward to new and exciting treatments for pediatric atopic dermatitis (AD).
“A new topical formulation (a phosphodiesterase-4 inhibitor) for pediatric AD is slated to be on the market in early 2017,” Dr. Price says. “Clinical trials for biologic therapies for severe pediatric AD will also be underway. There is currently little evidence-based literature supporting treatments for severe AD in childhood and adolescence. These new trials will be a welcomed addition, hopefully bringing better treatment options to the table.” (No conflicts)
It is an exciting time in dermatology, as there continues to be a shift in the understanding of the pathophysiology of many disease states, bringing new therapies for difficult to treat conditions, according to medical, cosmetic and surgical dermatologist Jennifer Salsberg, M.D., of Women's College Hospital, Toronto, Ontario.
“I am looking forward to the new treatments on the horizon for atopic dermatitis, both topical and systemic, especially new biologic agents targeting specific inflammatory mediators implicated in atopic dermatitis,” Dr. Salsberg says. “We will soon have exciting new options to help patients with this chronic and sometimes debilitating condition."
Read more at Dermatology Times >>
Atopic dermatitis treatment
Harper N. Price, M.D., pediatric dermatology division chief, Phoenix Children’s Hospital, tells Dermatology Times that she’s looking forward to new and exciting treatments for pediatric atopic dermatitis (AD).
“A new topical formulation (a phosphodiesterase-4 inhibitor) for pediatric AD is slated to be on the market in early 2017,” Dr. Price says. “Clinical trials for biologic therapies for severe pediatric AD will also be underway. There is currently little evidence-based literature supporting treatments for severe AD in childhood and adolescence. These new trials will be a welcomed addition, hopefully bringing better treatment options to the table.” (No conflicts)
It is an exciting time in dermatology, as there continues to be a shift in the understanding of the pathophysiology of many disease states, bringing new therapies for difficult to treat conditions, according to medical, cosmetic and surgical dermatologist Jennifer Salsberg, M.D., of Women's College Hospital, Toronto, Ontario.
“I am looking forward to the new treatments on the horizon for atopic dermatitis, both topical and systemic, especially new biologic agents targeting specific inflammatory mediators implicated in atopic dermatitis,” Dr. Salsberg says. “We will soon have exciting new options to help patients with this chronic and sometimes debilitating condition."
Read more at Dermatology Times >>
